Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Eli Lilly and Company (3)
65 Articles Available
3
3
Can't find what you're looking for? Try our
advanced search
.
Insulin
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
PR-M06-18-NI-084
Acquisition
Lilly Completes Acquisition of ARMO BioSciences
PR-M06-18-NI-078
Lilly to Acquire AurKa Pharma
PR-M05-18-NI-065
Acquisition
Eli Lilly Makes Two Acquisitions in the Oncology Space
PAO-M05-18-NI-008
Acquisition
Lilly Announces Agreement To Acquire ARMO BioSciences
PR-M05-18-NI-049
Collaboration
Boehringer Ingelheim and Lilly Announce an Academic Collaboration with University of Oxford
PR-M04-18-NI-64
Clinical Trials
Eli Lilly Gets Good News for Cyramza
PAO-M04-18-NI-009
Strategic Collaboration
Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes
PR-M04-18-NI-029
Biologics
Next Generation Biologics, Janssen's Tremfya, Eli Lilly's Taltz, and Novartis' Cosentyx, Raising the Bar in Psoriasis Management
PR-M03-18-NI-040
Results
Lilly Reports Results of Migraine Survey
PAO-M03-18-NI-007
Phase 3
Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
PR-M02-18-NI-61
CRO
Society for Clinical Research Sites Announces Winning Sponsor and CRO of 2017 Eagle Award — Eli Lilly and INC Research/InVentiv Health
PR-M10-17-NI-006
FDA Approval
Eli Lilly Gets Early Approval for Breast Cancer Drug
PAO-M10-17-NI-006
Drug Development
Lilly Tackling Autoimmune Diseases Using Antigen Technology from Topas Therapeutics
PAO-M09-17-NI-004
FDA
Lilly’s Breast Cancer Treatment Granted Priority Review
PAO-M07-17-NI-019
FDA
FDA Fast Track Designation Granted for Pfizer and Eli Lilly’s Innovative Pain Treatment
PAO-M06-17-NI-010
Innovation
Eli Lilly, KeyBioscience Agree to Work on the Development of New Diabetes Drugs
PAO-M06-17-NI-011
«
3
3
.svg)
